TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, of all races and ethnicities;~* Admitted voluntarily to the adult psychiatric inpatient at PRI;~* Suffering from a current depressive episode~* Reason for hospitalization should be a recent suicide attempt or suicidal ideation~* Current severe suicidal ideation defined by a score \>7 on the Beck Scale for Suicidal Ideation~* Ability to read, write and speak English.~Exclusion Criteria:~* History of dementia, neurovascular or neurodegenerative conditions~* Physical disabilities that prohibit task performance (such as blindness or deafness)~* Choosing to opt out of the research study.~* Additional exclusion criteria for TMS include the following:~  * a personal history or 1st degree relative with history of epilepsy;~ * a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines;~ * recent use of cocaine or alcohol;~ * ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators;~ * a pacemaker;~ * pregnancy (or the possibility of pregnancy);~ * Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002).~ * Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active rTMS (Type: ACTIVE_COMPARATOR): Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
- Sham rTMS (Type: SHAM_COMPARATOR): Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and provide written informed consent.~* Age 19-60, inclusive.~* Diagnosis documented according to DSM-IV of OCD.~* Exhibits moderate to severe OCD symptoms and a minimum score of 16 or greater -YBOCS at screening.~* Willing and able to discontinue current medications taken for the treatment of OCD.~* Able to attend and participate in all study visits.~* Agree to continue if in current psychosocial therapy throughout the remainder of the study.~* If female and of child-bearing potential, willing to use an acceptable method of birth control for the duration of the study.~* If male, willing to use barrier method of birth control or had previous vasectomy.~Exclusion Criteria:~* Have other DSM-IV Axis I diagnoses.~* Pregnant as confirmed by urine analysis, or lactating, or unwilling to comply with use of contraception.~* Unwilling or unable to washout (discontinue) from prohibited medications such as antidepressants (See Appendix 2).~* Depression symptoms with a score of 15 or greater on the MADRS at screening.~* Current suicidal ideation or plan within the last 30 days.~* Have a medical condition which, in the opinion of the investigator, makes study participation unsafe or noncompliant.~* Abnormal physical exam or laboratory values which, in the opinion of the investigator, makes study participation unsafe or may require introduction of concomitant medications during the course of the study.~* Benzodiazepine and/or similar sedative-hypnotic or anxiolytic use or abuse within 15 days of potential flumazenil treatment: patients must not be habituated to benzodiazepines and must provide a urine sample that is negative for benzodiazepines, must not be taking supra-therapeutic doses of zolpidem (AmbienTM) or zaleplon (SonataTM ). (See Appendix 2).~* Patients who are taking Phenobarbital for a documented seizure disorder can be admitted. Patients with a seizure disorder being managed with clonazepam (KlonopinTM ) or other benzodiazepine cannot participate, patients must not be taking TCA, lithium, methylxanthines, isoniazid, propoxyphene, monoamine oxidase inhibitors, bupropion HCL, and cyclosporine. (See Appendix 2).~* Previously treated with flumazenil for OCD.~* AIDS as determined by self-report.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Sugar Pill, Placebo (Type: PLACEBO_COMPARATOR): None
- Flumazenil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Synergistic Enteral Regimen for Treatment of the Gangliosidoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have a documented infantile or juvenile gangliosidosis disease.~2. Age: 17 years or less at time of enrollment~3. Subjects and their caregivers must be willing to work with a ketogenic diet team for management of the subject's ketogenic diet.~Exclusion Criteria:~1. A desire to not participate~2. Patients who are older than 17 years will not be enrolled in this study.~3. Children with severe renal impairment will not be enrolled in this study.~4. Post-pubertal females who are pregnant, or who are unwilling to use highly-effective methods to prevent pregnancy, will be excluded from this study.~5. Breast-feeding females will be excluded from this study.~6. Subjects who have an allergy to miglustat or any of the components within the drug product will be excluded from this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 204 Months
- Healthy Volunteers: f

Study Arms:
- Syner-G Therapy Regimen (Type: EXPERIMENTAL): The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Genetics of QT Response to Moxifloxacin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Genotype in the highest and lowest quintiles of genetic predictors of QT interval duration~* Able to swallow pills~Exclusion Criteria:~* Inability to provide informed consent~* Prior known cardiovascular, renal, hepatic disease~* Personal or family history of sudden cardiac death~* Current use of prescribed or over-the-counter medications as well as recreational drugs~* Resting bradycardia (defined as resting heart rate \< 50 bpm)~* Conduction disease (QRS \> 100ms)~* QTc prolongation on electrocardiography (QTc \> 500msec)~* Abnormal potassium or magnesium serum level~* Abnormal renal or liver function tests~* Women who are nursing, pregnant or planning to become pregnant during the study period~* Tendon disorder or rupture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Moxifloxacin group (Type: EXPERIMENTAL): Healthy volunteers with QT genotype score in the highest or lowest quintile
- Placebo group (Type: PLACEBO_COMPARATOR): Healthy volunteers with QT genotype score in the highest or lowest quintile

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with age above 18 years old~* Patient with diagnosis of ulcerative colitis for at least 6 months.~* Patient with mayo endoscopic score ≥ 1~* Patient with mild to moderate disease activity (3 \< SCCI \< 12)~* Ongoing treatment by mesalamine, steroids, thiopurines or Tumor Necrosis Factor antagonist at stable dose.~* Patients who have given written informed consent.~Exclusion Criteria:~* Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.~* Psychiatric disease that alter the judgment~* Stoma~* Proctocolectomy~* Severe disease (SCCI \>12, acute severe colitis)~* Steroid dose \> 10 mg/j or introduction of steroid (topic or oral) within 4 weeks~* Introduction or dose optimization of TNF antagonist within 4 months~* Introduction or dose optimization of thiopurine~* Hemoglobin level \< 11,5 g/dL, Platelets \> 400000/mm3, Leukocytosis \> 10 000/mm3~* Intolerant to lactose~* Disease extent limited to the rectum~* Mayo endoscopic subscore of 3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotics (Type: EXPERIMENTAL): Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 55 years of age.~2. Admitted to hospital with a disease of respiratory system including acute respiratory diseases (e.g., pneumonia, acute bronchitis) or exacerbation of existing respiratory diseases.~3. Anticipated length of hospital stay of at least 3 days.~4. Ability to climb a flight of 10 stairs or walk a city block without the help of another person prior to hospitalization.~5. Able to consume foods and beverages orally.~Exclusion Criteria:~1. Unstable heart failure which requires ICU admission.~2. Severe respiratory disease requiring long-term, continuous oxygen therapy.~3. Diabetes.~4. Impaired renal function.~5. Impaired liver function.~6. Cancer.~7. Hospitalized for two or more days in past 4 weeks.~8. Requires intubation or tube feeding.~9. Expected to be transferred to an advanced care unit.~10. Body mass index of ≥ 40 kg/m2.~11. Active tuberculosis.~12. Ascites or severe edema.~13. Acute Hepatitis or HIV.~14. Disorder of gastrointestinal tract.~15. Dementia;brain metastases, eating disorder, significant neurological, psychiatric disorder, other psychological condition.~16. Medication/dietary supplements/substances that could modulate metabolism or weight.~17. Partial or full artificial lower limb.~18. Allergy or intolerance to any of the ingredients in the study products.~19. Procedure using iodine-based contrast media within 7 days prior to hospitalization; or, anticipated to need procedure using iodine-based contrast media within 3 days after hospital admission.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Oral Nutrition Supplement (Type: EXPERIMENTAL): Experimental ONS orally Two 8 fl oz servings/day
- No Product (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 60 years or older~2. Diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic features by Diagnostic and Statistical Manual IV Text Revision (DSMIV-TR) criteria~3. Presence of hypertension (defined as systolic \> 140 or diastolic \> 90 or currently receiving antihypertensive therapy)~4. Minimum depression severity of ≥ 15 on the Montgomery-Asberg Depression Rating Scale (MADRS)~5. Cognitively intact or with mild cognitive deficits, with a minimum score ≥ 23 on the Montreal Cognitive Assessment (MoCA).~Exclusion Criteria:~1. Other psychiatric Axis I disorders~2. Acute suicidality~3. Electroconvulsive therapy in the last 6 months~4. Primary neurological disorder, including dementia and stroke~5. Significant cardiovascular disease, specifically diagnosis of congestive heart failure, known bilateral renal artery stenosis, symptomatic hypotension, or critical aortic or mitral stenosis~6. Myocardial infarction or open-heart surgery in last 6 weeks~7. Serum creatinine ≥ 265 micromol /L~8. Serum potassium ≥ 5.5 mmol/L~9. MRI contraindications~10. Known allergy to sertraline or candesartan specifically or known allergy to other SSRIs or ARBs.~11. History of prolonged (\> 3 weeks) or self-described severe discontinuation syndrome in the past after stopping an antidepressant.~12. Current use of an angiotensin receptor blocker~13. Current or planned psychotherapy~14. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge would be contraindicated or put the subject at increased risk. This would include acute respiratory disease, chronic angina, or other unstable cardiac conditions.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Sertraline (Type: EXPERIMENTAL): Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
- Phase 2: Candesartan (Type: EXPERIMENTAL): For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Performance of Echocardiography Performed by Emergency Physicians After a Basic Training

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients \> 18 years old~* patients admitted in the Emergency Department of Limoges University Hospital~* patients with circulatory failure defined as 1 or more of the following criteria :~* clinical signs of tissue hypoperfusion~* mottling~* Encephalopathy~* Oliguria \< 0.5 ml/kg/h~* biological signs of hypoperfusion~* Lactate \> 2 mmol/L~* AND/OR Low blood pressure defined as a sBP \< 90 mmHg or mBP \< 65 mmHG or decrease of sBP \> 40 mmHg compared with usual blood pressure~* OR Patients with signs of sepsis recently defined as the following :~* Suspicion of clinical infection~* At least 2 of the 3 following items (i.e. SOFA \> 2 points with 1 point/item) :~* Glasgow score \< 13~* Respiratory rate \> 22 cycle/min~* Systolic blood pressure \< 100 mmHg~Exclusion Criteria:~* Pregnant patients~* Moribund patients or with limited care~* Patients under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Circulatory failure (Type: None): Patients with a circulatory failure due to a sepsis or not

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Return of Function and External Rotation Post Proximal Humerus Fracture Fixation With Neutral Rotation Brace

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proximal humeral fractures requiring operative intervention with extramedullary plate fixation (i.e. fractures displaced by 1cm and/or angulated by 45 degrees or more)~* Age over 18 years of age~* Patient able to give informed consent~Exclusion Criteria:~* Patients having intra-operative findings to complete Pectoralis major rupture or if operative exposure requires complete Pectoralis major tenotomy. (These patients need to be held in internal rotation with a standard polysling to allow healing of the Pectoralis major tendon)~* Patients under 18 years of age~* Patients unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neutral Rotation Brace (Type: OTHER): Neutral Rotation Brace
- Standard polysling (Current practice) (Type: OTHER): Standard polysling (Current practice)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must give written informed consent~* Histologically confirmed adenocarcinoma of the prostate~* Biochemical relapse after primary radiation therapy or surgery~* Normal testosterone levels~* 3 rising PSA after nadir, with interval between PSA determinations \> 2 weeks~Exclusion Criteria:~* Local recurrence by CT scan~* Distant metastases by bone scan~* Hypercalcemia~* Nephrolithiasis~* Renal insufficiency (serum creatinine \> 1.8 mg/dl)~* Pancreatitis~* History of ulcer or gastrointestinal bleeding~* More than 6 months of hormone ablation therapy~* Concurrent therapy for prostate cancer~* Uncontrolled HTN~* H/O MI, CVA, TIA~* Known coronary disease/cerebrovascular disease~* Platelet counts \<50~* Patients on anticoagulants~* Patients on lithium

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Suitable veins for cannulation or repeated venipuncture~* Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and nor more than 100 kg~Exclusion Criteria:~* History of any clinically significancy disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study~* History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs~* Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy